wechat public accounts
Address: Building F2, No. 88, Kechuang 6th Street, Beijing Economic Development Zone
Tel: +86 010-56315466
Fax: +86 010-56315314
Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD. Beijing ICP preparation 17065868-1
Jacobio Pharmaceuticals Appoints Andrea Wang-Gillam, M.D. Ph.D., as Chief Medical Officer
BEIJING,China and BOSTON, US, July 16, 2020 - Jacobio Pharmaceuticals Co., Ltd today announced the appointment of Andrea Wang-Gillam, M.D., Ph.D., as its Chief Medical Officer and Senior Vice President.
In this role, Dr. Wang-Gillam will provide leadership in strategical development of Jacobio’s pipeline and oversee its global clinical operation. Prior to joining Jacobio, Dr. Wang-Gillam, a pancreatic cancer expert, served as Clinical Director of Gastrointestinal Oncology Program, Director of Developmental Therapeutics Program (Phase I Program) in the Division of Oncology of Department of Medicine at Washington University School of Medicine in St. Louis. Dr. Wang-Gillam brings over 13 years of academic experience in clinical and translation research.
Dr. Wang-Gillam is a well-known medical oncologist and researcher, especially in the field of gastrointestinal cancer and drug development. She has been a principal investigator (PI) for more than 60 clinical trials including the NAPOLI-1 study that led the approval of nanoliposomal irinotecan in the US, Europe and some regions in Asia. She has been either the PI or project leader for multi-institutional NIH grants such NCI Partner of Early Clinical Trials in Cancer (UM1), Pancreas Specialized Programs of Research Excellence (SPORE) and Patient-derived Xenografts and Clinical Trial Network grant (U54). Dr. Wang-Gillam’s expertise has landed her the role of serving as a member for NCI Pancreatic Cancer Task Force and the GI Committee of ALLANCE and Scientific Program Committee of the American Society of Clinical Oncology (ASCO). Dr. Wang-Gillam is very collaborative and productive and she has been an author on 90 peer-reviewed articles including being the first author of papers published in Lancet, Lancet Oncology, Journal of Clinical Oncology and other high impact journals.
Yinxiang Wang, Ph.D., Jacobio’s CEO and Chairman said, “We are very pleased that Andrea becomes a key member of our executive management team. Andrea's joining will advance our clinical strategic leadership and accelerate the global development of our pipeline”.
Jacobio Pharmaceuticals Co., Ltd. is committed to providing more products and solutions to people's health. Our mission and vision are "For Patients" and to develop innovative drugs globally. The company's R&D centers are located in Beijing and Boston, with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors. The company is financed by several top-tier investors, including QiMing ,Lilly Asia Ventures, Hillhouse and BioEngine.